• Hanmi – Aptose enter into exclusive WW license agreement

    $420 mil deal of HM43239: an oral, highly potent, myeloid kinome inhibitor (MKI) to target leukemia

  • Hanmi, LegoChem collaborate to develop bispecific ADC cancer drugs

    Using Beijing Hanmi’s Pentambody™ to develop a novel cancer treatment

  • Hanmi, DKU to develop resistant lung cancer-targeted therapy

    Research collaboration on innovative new drug targeting resistant lung cancer

  • Hanmi, GC to co-research/develop rare diseases treatments

    Jointly develop a treatment for LSD using patents currently owned by Hanmi

  • Hanmi to manufacture Genexine’s COVID-19 vaccine

    Signed a contract to develop the GX-19N (DNA vaccine) production process and manufacturing

  • Hanmi promotes clinical use of Keytruda® combi with FLX475

    Phase II begins for gastric cancer patients in Korea and China in 1H 2021.

  • Hanmi and Merck Enter into Licensing Agreement to Develop Efinopegdutide

    Once-weekly therapy for Nonalcoholic Steatohepatitis (NASH)

  • Hanmi Pharm partners with RAPT

    Hanmi announces collaboration with RAPT Therapeutics to develop and commercialize FLX475 for cancer treatment

  • Hanmi Pharm-GC Pharma

    Hanmi Pharm & GC Pharma team up to develop rare disease treatment

  • Hanmi-Standigm

    Hanmi Pharm signs an agreement with Standigm to find drug candidates based on AI

  • Licensing Agreement with Phanes

    Hanmi and Phanes announce licensing agreement to develop bi- and/or multi-specific antibodies

  • “Gugu” to enter Japanese Market

    Hanmi’s impotence drug “Gugu” enters Japanese market with “BPH” and Sandoz will take charge of sales.

  • Co-promotion Agreement with Santen

    Hanmi and Santen sign co-promotion accord for dry eye treatments

  • Hanmi/Beijing Hanmi, Innovent agree to co-
    develop bispecific anticancer antibody

    Hanmi Pharmaceuticals and Innovent Biologics signed
    a global partnership to develop a immuno-oncology bispecific antibody

  • License agreement with Genentech for a novel
    oral RAF inhibitor

    Hanmi enters into an exclusive development with Genentech for the development and commercialization
    of Hanmi’s pan-RAF inhibitor, HM95573, which is currently in Phase I clinical development

  • Hanmi-MSD sign contract to export
    ROSUZET to 23 countries

    Hanmi Pharm responsible for R&D and manufacturing of ROSUZET; MSD responsible for marketing and sales in importing countries

  • Research collaboration for new anti-cancer drug with Ajou Univ.

    Research collaboration to develop novel anti-cancer drug using stem cells covering glioblastoma and various cancer

  • Licensing agreement for new lung cancer drug with ZAI Lab

    Licensing agreement to grant exclusive rights in China (including Hong Kong and Macao) for new lung cancer drug targeting resistance, HM61713, with ZAI Lab, a biotechnology company based in Shanghai, China

  • Technology transfer of new biologics to Janssen

    Licensing agreement for development and commercialization of long-acting GLP-1/Glucagon receptor dual agonist ‘HM12525A’ for the treatment of diabetes and obesity with Janssen, a pharmaceutical company based in New Jersey, USA

  • Technology transfer of new diabetes program to Sanofi

    Licensing agreement for Quantum Project, a long-acting diabetes program, with Sanofi, a pharmaceutical company based in Paris, France

  • Licensing agreement for immunological therapy with Eli Lilly

    Exclusive licensing and collaboration agreement for BTK inhibitor, HM71224, with Eli Lilly, a pharmaceutical company based in Indiana, USA

  • License out Poziotinib to Spectrum (US)

    Worldwide licensing agreement excluding Korea and China, for clinical development, manufacturing, marketing approval and commercialization of Poziotinib with Spectrum baseed in Nevada State, USA

  • Strategic investment in US R&D venture specialized in ophthalmology

    License and co-development rights of Luminate® , novel drug for a retina-related disease, through strategic investment in Allegro Ophthalmics based in California, USA

  • License out Poziotinib to Luye Pharma (China)

    Exclusive licensing agreement for clinical development, manufacturing and approval and sales and marketing after commercialization of Poziotinib in China with Luye Pharma, based in Yantai, China

  • Co-promotion for diabetes medicines with multinational pharmaceutical company

    Co-promotion of anti-diabetic treatment Galvus ® and Galvus MET®, DPP-IV inhibitors, with Novartis, a Swiss multinational pharmaceutical company

  • Licensing agreement for new drug for neutropenia

    Licensing agreement for worldwide license, excluding Korea, China and Japan, for a new medicine for neutropenia with Spectrum based in California, USA

  • Export of ORASCOVERY technology to Athenex (US)

    Licensing agreement with Anthenex, headquatered in NY, for development and commercialization in the US, Europe, etc. of ORASCOVERY technology and a new oral anticancer drug developed using this technology.